Complications After Epilepsy Surgery

Sponsor
First Affiliated Hospital Xi'an Jiaotong University (Other)
Overall Status
Completed
CT.gov ID
NCT04727892
Collaborator
(none)
2,026
199

Study Details

Study Description

Brief Summary

Epilepsy surgery is effective for refractory epilepsy, particularly focal epilepsy, but is still underutilized worldwide. In the United States, the annual percentage of surgical procedures for refractory epilepsy was low (range: 0.35%-0.63%) from 2003 to 2012. Fear associated with the risks of invasive procedures may be the reason for the cautious attitude towards epilepsy surgery. Therefore, the risks of epilepsy surgery in the modern age need to be evaluated thoroughly and precisely to improve epilepsy surgery outcomes.

The safety of epilepsy surgery has been confirmed in several studies. Studies on this topic with large sample sizes (> 500 patients) were either multicenter or covered a long study period. In addition, high-resolution magnetic resonance imaging (MRI) was not used in the early stage in these studies. Differences in medical environment among epilepsy centers and advancements in presurgical evaluations and surgical techniques over time may have caused heterogeneity and biases, thereby limiting the quality of these studies. Over the past two decades, there was no large-scale studies on post-epilepsy surgery complications performed at a single center. Moreover, surgery-related complications are seldom graded according to severity. Especially, the risk factors for these complications remain unclear.

Condition or Disease Intervention/Treatment Phase
  • Procedure: epilepsy surgery

Detailed Description

Epilepsy, involving a persistent predisposition to seizure, is one of the most common chronic neurological disorders, affecting more than 65million people worldwide. Epilepsy not only negatively impacts patients'education, employment, and social contact, but also imposes a serious burden on patients'families and on society. Notably, epilepsy is the second most burdensome neurological disorder, accounting for 0.7% of disability-adjusted life years worldwide, according to the World Health Organization's 2010 Global Burden of Disease study, making it a global public health issue.

Furthermore, about 40% of patients respond poorly to the first 2 antiepileptic drugs and have medically refractory epilepsy. Epilepsy surgery is effective for refractory epilepsy, particularly focal epilepsy, but is still underutilized worldwide. In the United States, the annual percentage of surgical procedures for refractory epilepsy was low (range: 0.35%-0.63%) from 2003 to 2012. Moreover, the number of surgical procedures for mesial temporal sclerosis (the most common type of refractory epilepsy) declined by more than half from 2006 to 2010. Fear associated with the risks of invasive procedures may be the reason for the cautious attitude towards epilepsy surgery. Therefore, the risks of epilepsy surgery in the modern age need to be evaluated thoroughly and precisely to improve epilepsy surgery outcomes.

The safety of epilepsy surgery has been confirmed in several studies. From 1980 to 2012, neurological deficits following epilepsy surgery decreased with time, from 41.8% to 5.2% in temporal resections and from 30.2% to 19.5% in extratemporal resections. However, studies on this topic with large sample sizes (> 500 patients) were either multicenter or covered a long study period. In addition, high-resolution magnetic resonance imaging (MRI) was not used in the early stage in these studies. Differences in medical environment among epilepsy centers and advancements in presurgical evaluations and surgical techniques over time may have caused heterogeneity and biases, thereby limiting the quality of these studies. Over the past two decades, there was no large-scale studies on post-epilepsy surgery complications performed at a single center. Moreover, surgery-related complications are seldom graded according to severity. Especially, the risk factors for these complications remain unclear.

Understanding the incidence and severity of complications after epilepsy surgery and the associated risk factors is beneficial, allowing physicians to provide patients with adequate surgical advice, and allowing patients to make rational decisions regarding epilepsy surgery. Furthermore, this information may help in the prevention of postoperative complications and improve our understanding of the procedures. Therefore, we reported the incidence of complications occurring in a three-month period after epilepsy surgery performed by the single neurosurgeon at the single center, identified the associated risk factors, and developed a nomogram for individually predicting the probability of complications.

Study Design

Study Type:
Observational
Actual Enrollment :
2026 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Severity Grading, Risk Factors and Prediction Model of Complications After Epilepsy Surgery: a Single-center, Large-scale and Retrospective Study
Actual Study Start Date :
Oct 1, 2003
Actual Primary Completion Date :
Apr 30, 2019
Actual Study Completion Date :
May 1, 2020

Arms and Interventions

Arm Intervention/Treatment
complications after epilepsy surgery

Group A with no complication; Group B with complications

Procedure: epilepsy surgery
Surgical procedures were individually designed according to the presurgical evaluation findings. Standard epilepsy surgery procedures were applied. Generally, surgical procedures were divided into curative and palliative surgery. Curative surgery included resection and disconnection of the epileptogenic zone. Palliative surgery included corpus callosotomy for bilateral synchronous onset and multiple subpial transections for epileptic foci located in the eloquent cortex. For widespread epileptogenic zones, multiple surgical techniques were combined.

Outcome Measures

Primary Outcome Measures

  1. Complications [in the 3-month period after epilepsy surgery]

    Complications included neurologic deficit, cerebral edema, intracranial hemorrhage, infection, hydrocephalus, subdural effusion, subcutaneous cerebrospinal fluid accumulation, and poor wound healing. Neurologic deficit was classified as either transient (resolving within 3 months) or persistent (lasting more than 3 months) Complication severity was categorized into four grades based on the therapeutic regimen: grade I, minor complications, conservative treatment; grade II, major complications; grade III, life-threatening complications requiring invasive treatment under general anesthesia or monitoring in the intensive care unit; grade IV, death.

Secondary Outcome Measures

  1. Predictors of complications. [in the 3-month period after epilepsy surgery]

    Potential factors included the preoperative, intra-operative, and postoperative clinical characteristics, such as sex, age at surgery, duration of seizure, previous medical history, pathology, serial number of surgery, invasive electrode implantation, type of surgical procedure, surgery duration, intra-operative blood loss, and acute postoperative seizure. Risk factors for complications were determined by using univariate and multivariate logistic regression analyses. Variables with P< .10 were selected as a potential risk factors and included in the multivariate logistic regression analysis. The forward stepwise method was used to select the variables that were eventually included in the model. Odds ratio (OR) and 95% confidence interval (CI) were calculated.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • (i) medically refractory epilepsy defined by the International League Against Epilepsyc; (ii) epilepsy surgery performed by a single neurosurgeon, Dr. H.Z.; (iii) surgical procedure performed via craniotomy.
Exclusion Criteria:
  • Patients with neuromodulation therapy were excluded in this study.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • First Affiliated Hospital Xi'an Jiaotong University

Investigators

  • Study Chair: Hua Zhang, PhD, First Affiliated Hospital Xi'an Jiaotong University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zhang Hua, Doctor, First Affiliated Hospital Xi'an Jiaotong University
ClinicalTrials.gov Identifier:
NCT04727892
Other Study ID Numbers:
  • XJTU1AF2020LSK-167
First Posted:
Jan 27, 2021
Last Update Posted:
Jan 27, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Zhang Hua, Doctor, First Affiliated Hospital Xi'an Jiaotong University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 27, 2021